Mounjaro – Page 2

Lilly’s Blockbuster GLP-1 Drugs Removed from FDA Shortage List

9 months ago talkbio0Tagged Drug Shortage, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, United States Food and Drug Administration, Zepbound

Lilly, GLP-1, FDA, drug shortage, Mounjaro, Zepbound, tirzepatide

Eli Lilly’s Mounjaro and Zepbound Return to Stock After Extended Shortage, FDA Announces

9 months ago talkbio0Tagged Diabetes, Drug Shortage, Eli, Eli Lilly, Mounjaro, United States Food and Drug Administration, Weight Loss Medication, Zepbound

Eli Lilly, Mounjaro, Zepbound, FDA, drug shortage, weight loss medication, diabetes medication

Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns

9 months ago talkbio0Tagged agonists, China, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Nordisk, Obesity, semaglutide, tirzepatide, Wegovy, Weight Loss, Zepbound

Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy

Lilly Expands Legal Efforts Against Compounded Tirzepatide Sellers, Warns of Counterfeit Risks

10 months ago talkbio0Tagged Compound, Eli, Eli Lilly, Legal, Mounjaro, patient safety, Zepbound

Eli Lilly, tirzepatide, Mounjaro, Zepbound, compounded drugs, counterfeit products, legal actions, patient safety

Lilly’s Tirzepatide Wins NICE Endorsement for Obesity Treatment with BMI and Weight Loss Conditions

11 months ago talkbio0Tagged Agonist, Body mass index procedure, Eli Lilly, Endorsement, Glucagon-Like Peptide-1 Receptor, Mounjaro, NICE, Nitroglycerin/Sodium Citrate/Ethanol Solution, Obesity, Zepbound

Lilly, tirzepatide, NICE endorsement, obesity treatment, BMI, weight loss, Zepbound, Mounjaro, GLP-1 receptor agonist

Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###

11 months ago talkbio0Tagged alpha 1-antitrypsin, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Indiana, Manufacture, Mounjaro, Nordisk, Obesity, Zepbound

Eli Lilly, Diabetes, Obesity, Mounjaro, Zepbound, Tirzepatide, Indiana, Manufacturing, API, Novo Nordisk, GLP-1 drugs

Eli Lilly Invests $5.3 Billion to Boost Production of Mounjaro and Zepbound

11 months ago11 months ago talkbio0Tagged Diabetes, Drug Industry, eli lilly, Investments, Manufacture, Mounjaro, Obesity, Weight Loss, Zepbound

** Eli Lilly, Mounjaro, Zepbound, Manufacturing, Investment, Diabetes, Obesity, Weight Loss, Pharmaceutical Industry

Lilly’s Future Brightens with Increased Visibility on Mounjaro and Zepbound Production Capacity

12 months ago talkbio0Tagged Capacity, Drug Industry, drug manufacturing, Eli Lilly, financial outlook, Mounjaro, production, Zepbound

Lilly, Mounjaro, Zepbound, production capacity, financial outlook, pharmaceutical industry, drug manufacturing.

Eli Lilly Expands Manufacturing Capacity with Nexus Plant Acquisition Amid Ongoing Mounjaro and Zepbound Supply Challenges

1 year ago talkbio0Tagged Acquisition (action), Capacity, Drug Industry, Drug shortages, Eli, Eli Lilly, Manufacture, Mounjaro, Nexus manufacturing, Plants, Wisconsin, Zepbound

Eli Lilly, Nexus manufacturing plant, Wisconsin, Mounjaro, Zepbound, drug shortages, manufacturing capacity, pharmaceutical industry, acquisition

Medicare Coverage Gap Linked to Reduced Prescription Rates for GLP-1 Weight Loss Drugs

1 year ago talkbio0Tagged Glucagon-Like Peptide 1, Health Care Costs, liraglutide, Lower prescription rates, Medicare, Mounjaro, Obesity, Saxenda, semaglutide, tirzepatide, Truveta study, Wegovy

GLP-1 drugs, Medicare coverage gap, Lower prescription rates, Obesity treatment, Semaglutide (Wegovy), Tirzepatide (Mounjaro), Liraglutide (Saxenda), Healthcare costs, Truveta study